Pharma giant Moderna and its partner Merck said on Wednesday (July 26) that they had begun taking in patients for a late-stage study testing their personalised skin cancer vaccine in combination with immunotherapy Keytruda.

Mid-stage study data obtained from 157 patients had yielded that the vaccine combination reduced the risk of recurrence of the disease or death by 44 per cent in patients with melanoma. It is the most deadly form of skin cancer

The current trial is expected to involve more than 1000 patients from over 25 countries. First patients are being enrolled in Australia.

The companies are testing the vaccine in melanoma patients whose tumors were surgically removed before being treated with either the drug-vaccine combination or Keytruda alone.

The vaccine is tailored for each patient to generate T-cells, a key part of the body's immune response, based on the specific mutational signature of a tumor.

Merck's Keytruda therapy is so-called checkpoint inhibitor. The therapy is designed to disable a protein called programmed death or PD-1. This protein helps cancer to evade the immune system.

<h2>The competition</h2>

In addition to Moderna and Merck, rival companies BioNTech SE and Gritstone Bio are also working on cancer vaccines based on mRNA technology.

For decades, scientists have been chasing the dream of vaccines against cancer. There have not been many successes.

According to industry experts, mRNA vaccines, which can be produced in as little as eight weeks, paired with drugs that rev up the immune system may lead to a new generation of cancer therapies.

The late-stage trial's main goal is to measure amount of time the patients live without the cancer returning when treated with the combination, compared to treatment with Keytruda alone.

The duration of the study would depend on when that occurs, the companies said.

(With inputs from agencies)

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us <a href="https://www.wionews.com/content-contribution-registration-form">here</a>.

WATCH WION LIVE HERE

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false"><iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

&nbsp;

Pharma giant Moderna and its partner Merck said on Wednesday (July 26) that they had begun taking in patients for a late-stage study testing their personalised skin cancer vaccine in combination with immunotherapy Keytruda.

Pharma giant Moderna and its partner Merck said on Wednesday (July 26) that they had begun taking in patients for a late-stage study testing their personalised skin cancer vaccine in combination with immunotherapy Keytruda. Mid-stage study data obtained from 157 patients had yielded that the vaccine combination reduced the risk of recurrence of the disease or death by 44 per cent in patients with melanoma. It is the most deadly form of skin cancer The current trial is expected to involve more than 1000 patients from over 25 countries. First patients are being enrolled in Australia. The companies are testing the vaccine in melanoma patients whose tumors were surgically removed before being treated with either the drug-vaccine combination or Keytruda alone. The vaccine is tailored for each patient to generate T-cells, a key part of the body's immune response, based on the specific mutational signature of a tumor. Merck's Keytruda therapy is so-called checkpoint inhibitor. The therapy is designed to disable a protein called programmed death or PD-1. This protein helps cancer to evade the immune system. The competition In addition to Moderna and Merck, rival companies BioNTech SE and Gritstone Bio are also working on cancer vaccines based on mRNA technology. For decades, scientists have been chasing the dream of vaccines against cancer. There have not been many successes. According to industry experts, mRNA vaccines, which can be produced in as little as eight weeks, paired with drugs that rev up the immune system may lead to a new generation of cancer therapies. The late-stage trial's main goal is to measure amount of time the patients live without the cancer returning when treated with the combination, compared to treatment with Keytruda alone. The duration of the study would depend on when that occurs, the companies said. (With inputs from agencies) You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here. WATCH WION LIVE HERE ×

Moderna/Merck kick off late-stage study of skin cancer vaccine

Cancer vaccine trials will begin in the United Kingdom in 2023 after the Rishi Sunak government signed a deal with German biopharmaceutical firm BioNTech to conduct clinical trials. The British patients are set to be enrolled for the clinical trials in autumn, The Telegraph reported.

The report said that a lab of around 70 scientists will be created in Cambridge to spearhead the research. BioNTech will also set up a London-based office as its UK headquarters, it added.

Cancer vaccine trials: What is expected?

The BioNTech cancer vaccines are not preventative. That is, in conventional sense, a public vaccination programme on the lines of smallpox or COVID-19 vaccination programmes, cannot be held to prevent cancer.&nbsp;The BioNTech cancer vaccines, instead,&nbsp;are designated as "therapeutic tools" to fight already diagnosed cancer and advanced tumours.&nbsp;

WATCH |&nbsp;<a href="https://www.wionews.com/videos/gravitas-a-knife-which-can-detect-cancer-in-seconds-549519">Gravitas: A knife which can detect cancer in seconds</a>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-a-knife-which-can-detect-cancer-in-seconds-549519/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a>

&nbsp;
</div>

It is expected that once the vaccines are found to be safe and effective, as many as 10,000 doses will be given to UK patients by 2030.

ALSO READ |&nbsp;<a href="https://www.wionews.com/science/in-a-first-scientists-use-artificial-dna-to-kill-cancer-cells-heres-what-you-need-to-know-547276">Explained: In a first, scientists use artificial DNA to kill cancer cells</a>

Professor Ugur Sahin, the chief executive and co-founder of BioNTech said in an official statement that the success of the upcoming trial will enable a worldwide roll out of such vaccines in the future.

"If successful, this collaboration has the potential to improve outcomes for patients and provide early access to our suite of cancer immunotherapies as well as to innovative vaccines against infectious diseases in the UK and worldwide," Professor Ugur Sahin said.&nbsp;

Cancer vaccine trials: Which forms of cancer will be targeted?

The forms of cancer, including breast, lung and pancreatic, will reportedly be targeted by BioNTech’s vaccine technology. The vaccines will be administered to early and late-stage cancer patients, targeting both active cancer cells and setting up a course of action in the body to prevent their return.

According to the World Health Organisation, Cancer is a leading cause of death worldwide. It was reported to have accounted for 10 million worldwide deaths in 2020.

WATCH WION LIVE HERE

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1  width=&quot;100%&quot;"></iframe>

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us <a href="https://www.wionews.com/content-contribution-registration-form">here</a>.

Cancer vaccine trials will begin in the United Kingdom in 2023 after the Rishi Sunak government signed a deal with German biopharmaceutical firm BioNTech to conduct clinical trials.

Cancer vaccine trials will begin in the United Kingdom in 2023 after the Rishi Sunak government signed a deal with German biopharmaceutical firm BioNTech to conduct clinical trials. The British patients are set to be enrolled for the clinical trials in autumn, The Telegraph reported. The report said that a lab of around 70 scientists will be created in Cambridge to spearhead the research. BioNTech will also set up a London-based office as its UK headquarters, it added. Cancer vaccine trials: What is expected? The BioNTech cancer vaccines are not preventative. That is, in conventional sense, a public vaccination programme on the lines of smallpox or COVID-19 vaccination programmes, cannot be held to prevent cancer. The BioNTech cancer vaccines, instead, are designated as "therapeutic tools" to fight already diagnosed cancer and advanced tumours. WATCH | Gravitas: A knife which can detect cancer in seconds × It is expected that once the vaccines are found to be safe and effective, as many as 10,000 doses will be given to UK patients by 2030. ALSO READ | Explained: In a first, scientists use artificial DNA to kill cancer cells Professor Ugur Sahin, the chief executive and co-founder of BioNTech said in an official statement that the success of the upcoming trial will enable a worldwide roll out of such vaccines in the future. "If successful, this collaboration has the potential to improve outcomes for patients and provide early access to our suite of cancer immunotherapies as well as to innovative vaccines against infectious diseases in the UK and worldwide," Professor Ugur Sahin said. Cancer vaccine trials: Which forms of cancer will be targeted? The forms of cancer, including breast, lung and pancreatic, will reportedly be targeted by BioNTech’s vaccine technology. The vaccines will be administered to early and late-stage cancer patients, targeting both active cancer cells and setting up a course of action in the body to prevent their return. According to the World Health Organisation, Cancer is a leading cause of death worldwide. It was reported to have accounted for 10 million worldwide deaths in 2020. WATCH WION LIVE HERE You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

Rishi Sunak govt signs deal with BioNTech for landmark Cancer vaccine trials

cancer-vaccine-trials

Cancer Vaccine Trials, News on Cancer Vaccine Trials, stories on Cancer Vaccine Trials, articles on Cancer Vaccine Trials, Cancer Vaccine Trials stories at Wion, Cancer Vaccine Trials news, Cancer Vaccine Trials latest news

cancer vaccine-trials

Moderna/Merck kick off late-stage study of skin cancer vaccine

Rishi Sunak govt signs deal with BioNTech for landmark Cancer vaccine trials